
301 Moved Permanently
301 Moved Permanently 301 Moved Permanently
Cemiplimab | Cancer Information | Cancer Research UK
Cemiplimab is a type of immunotherapy. It is a treatment for advanced cutaneous squamous cell carcinoma (SCC).
Symptoms of acute myeloid leukaemia (AML) - Cancer Research UK
Symptoms of AML can include feeling tired, frequent infections, high temperature and bruising easily. Find out more about the symptoms of AML. Read about possible symptoms of acute myeloid …
Looking after your stoma - Cancer Research UK
Looking after your stoma A stoma is a hole (opening) made in the skin in front of your neck to allow you to breathe. It is at the base of your neck. Through this hole, air enters and leaves your windpipe …
Fibrocystic breast changes - Cancer Research UK
Fibrocystic breast changes Fibrocystic breast changes are a non cancerous (benign) condition. It can also be called fibrocystic breast disease. Many women have fibrocystic changes in their breasts at …
Cancer Research UK
Cancer is relentless. But so are we. Whether you fundraise, pledge to leave a gift in your will or donate. Every part supports life-saving research. Play your part and together we will beat cancer. If you've …
Cervical screening - Smear test | Cancer Research UK
Nov 27, 2024 · Cervical screening is a way of preventing cervical cancer. It is not a test for cancer. It tests for a virus called human papillomavirus (HPV).
RICE | Cancer information | Cancer Research UK
Jun 12, 2023 · Rituximab, ifosfamide, carboplatin, and etoposide (RICE) is a combination of cancer drugs. It is a treatment for non-Hodgkin lymphoma or Hodgkin lymphoma.
Rope 4 Hope Committee member, volunteer or participant
We are looking for ambitious individuals who love to skip and can combine their love for the sport to join in The Big Skip and fundraise for life-saving research.
Do mobile phones or Wi-Fi cause cancer? - Cancer Research UK
Dec 20, 2024 · Using mobile phones does not increase your risk of cancer. 4G, 5G, Wi-Fi and wireless devices don’t cause cancer.